Advertisement
UK markets close in 3 hours 2 minutes
  • FTSE 100

    8,225.08
    +19.97 (+0.24%)
     
  • FTSE 250

    20,436.36
    +55.31 (+0.27%)
     
  • AIM

    773.73
    -3.77 (-0.48%)
     
  • GBP/EUR

    1.1827
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2686
    -0.0036 (-0.28%)
     
  • Bitcoin GBP

    51,987.88
    +686.89 (+1.34%)
     
  • CMC Crypto 200

    1,376.58
    -6.08 (-0.44%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CRUDE OIL

    81.59
    +0.02 (+0.02%)
     
  • GOLD FUTURES

    2,352.70
    +5.80 (+0.25%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     
  • DAX

    18,145.92
    +78.01 (+0.43%)
     
  • CAC 40

    7,624.99
    +54.79 (+0.72%)
     

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

scPharmaceuticals, Inc.
scPharmaceuticals, Inc.

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 5:00PM ET. Mr. Tucker will also be meeting with investors that day.

A webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com